Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 150Stomach Neoplasms 52Neoplasms 49Pancreatic Neoplasms 41Neoplasm Metastasis 32Squamous Cell Carcinoma of Head and Neck 26Head and Neck Neoplasms 25Esophageal Neoplasms 24Colonic Neoplasms 22Rectal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Esophageal Squamous Cell Carcinoma 15Adenocarcinoma 14Adenocarcinoma Of Esophagus 12Cholangiocarcinoma 11Biliary Tract Neoplasms 11Ovarian Neoplasms 9Triple Negative Breast Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Urinary Bladder Neoplasms 6Sarcoma 6Keratosis, Actinic 6Gastrointestinal Neoplasms 6Endometrial Neoplasms 6Carcinoma, Squamous Cell 6Advanced Solid Tumors 6

Interventions

Pemetrexed 5ponatinib 4pembrolizumab 4Carboplatin 4Cisplatin 3130-nm albumin-bound paclitaxel 3tetulomab tetraxetan lu-177 2pralsetinib 2osimertinib 2napabucasin 2fludarabine 2ficlatuzumab 2entinostat 2durvalumab 2atezolizumab 2Rituximab 2Paclitaxel 2Lutetium 2Irinotecan 2Immunotherapy 2Imatinib Mesylate 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2vorasidenib 1siltuximab 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Histologic Type × Fluorouracil × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡